C5 Lenalidomide
Based on 1 Customer Validation
C5 Lenalidomide is a 5-amino-substituted Thalidomide (HY-14658) analog. C5 Lenalidomide inhibits LPS (HY-D1056)-stimulated TNF-α production.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.40%
- CAS 番号: 191732-70-4
- 分子式: C13H13N3O3
- 分子量:259.26
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-43722
Lenalidomide-Br -
HY-W072954
Lenalidomide-5-Br -
HY-W244657
3-(6-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dioneLenalidomide Analog -
HY-A0003
LenalidomideImmunomodulator -
HY-100507
AvadomideCereblon Modulator -
HY-N0472
GeraniinTNF Receptor Inhibitor -
HY-110203
R-7050TNF Receptor Antagonist -
HY-A0003R
Lenalidomide (Standard)Reference Standard -
HY-N0029
Forsythoside BTNF Inhibitor -
HY-111255
SPD304TNFα Inhibitor -
HY-N0619
Mulberroside ATyrosinase Inhibitor -
HY-N0267
HypaconitineTNF Receptor Inhibitor
生物活性
製品説明
IC50 & Target
|
Cereblon |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PBMC | IC50 |
>100 μM
Compound: Page no 420, R4C1, cpd 1
|
Antiinflammatory activity in human PBMC cells assessed as reduction in LPS-induced TNF-alpha production preincubated for 1 hr followed by LPS addition and measured after 18 to 20 hrs by ELISA
Antiinflammatory activity in human PBMC cells assessed as reduction in LPS-induced TNF-alpha production preincubated for 1 hr followed by LPS addition and measured after 18 to 20 hrs by ELISA
|
[PMID: 31125896] |
体外実験
化学情報
-
CAS 番号 191732-70-4
-
性状 Solid
-
分子量 259.26
-
分子式 C13H13N3O3
-
Color Gray to dark gray
-
SMILES
O=C(C(N(CC1=C2C=CC(N)=C1)C2=O)CC3)NC3=O
-
別名
Lenalidomide 5'-amine
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (192.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (270 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8571 mL | 19.2857 mL | 38.5713 mL | 96.4283 mL |
| 5 mM | 0.7714 mL | 3.8571 mL | 7.7143 mL | 19.2857 mL | |
| 10 mM | 0.3857 mL | 1.9286 mL | 3.8571 mL | 9.6428 mL | |
| 15 mM | 0.2571 mL | 1.2857 mL | 2.5714 mL | 6.4286 mL | |
| 20 mM | 0.1929 mL | 0.9643 mL | 1.9286 mL | 4.8214 mL | |
| 25 mM | 0.1543 mL | 0.7714 mL | 1.5429 mL | 3.8571 mL | |
| 30 mM | 0.1286 mL | 0.6429 mL | 1.2857 mL | 3.2143 mL | |
| 40 mM | 0.0964 mL | 0.4821 mL | 0.9643 mL | 2.4107 mL | |
| 50 mM | 0.0771 mL | 0.3857 mL | 0.7714 mL | 1.9286 mL | |
| 60 mM | 0.0643 mL | 0.3214 mL | 0.6429 mL | 1.6071 mL | |
| 80 mM | 0.0482 mL | 0.2411 mL | 0.4821 mL | 1.2054 mL | |
| 100 mM | 0.0386 mL | 0.1929 mL | 0.3857 mL | 0.9643 mL |
C5 Lenalidomide 関連分類
HY-132248 関連分類
Powered by Bioz